Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07650864

The Effect of Foot Massage With a Massage Roller on Chemotherapy-Related Neuropathic Pain

Chemotherapy-related neuropathic pain is experienced by 30-40% of cancer patients. This pain significantly reduces the quality of life and overall well-being of patients battling cancer. Studies widely acknowledge that standardizing neuropathic pain assessment leads to improved patient outcomes. Our project, which we believe will add a different dimension to nursing care for cancer patients, aims to reduce chemotherapy-related neuropathic pain experienced by cancer patients through foot massage. The study population will consist of male and female cancer patients with chemotherapy-related neuropathic pain (VAS ≥ 4/10), over 18 years of age, who are actively undergoing treatment at the Medical Oncology Clinics of Atatürk University Research Hospital between February 1, 2026 and June 30, 2026, and who are not scheduled for surgical procedures during the research period. Accordingly, the minimum number of participants required for the study has been determined as 52. To reduce the risk of possible losses, withdrawals, or missing data during the research process, it is planned to include more participants than the calculated sample size. Within the scope of the research, the Neuropathic Pain Scale (S-LANSS) will be used to determine the presence of neuropathic pain in patients, and the VAS will be used to determine the severity of the pain. After the pre-test is completed, the control group will continue with routine treatment and care in the clinic. The intervention group will receive routine treatment and care, as well as foot massage using a foot massage roller for a total of 30 minutes twice a day. This intervention in the intervention group is planned to continue for 3 weeks. During this period, no other treatment will be applied to patients for neuropathic pain. The fact that only 3 small-scale studies, including one case report, were found in the literature review on this subject, the multidisciplinary collaboration in planning this study, and the expectation that it will offer practical solutions for chemotherapy-related neuropathic pain highlight the originality of the study. It is expected that the results obtained will provide evidence-based contributions to nursing care, support holistic approaches to improving patient comfort, and develop a viable intervention model for healthcare professionals.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Atatürk Üniversitesi

Erzurum, 25080, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≥18 years of age
  • receiving takzan and platinum group chemotherapy,
  • not receiving oxoplatin treatment
  • vas pain ≥ 6
  • no surgical treatment plan
  • voluntary participation

Exclusion criteria

  • psychiatric disorder
  • treatments other than chemotherapy
  • receiving oxoplatin treatment
  • communication disorder
  • planned surgical procedure

Treatment and study plan

Roller Massage

Other

intervention group

Ice therapy

Other

control group

Primary outcomes

  1. Pain score

    Time frame: 3 weeks

    pain score vas<6

Sponsors and collaborators

Lead sponsor

Ataturk University

Other

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jun 16, 2026
Registry last updated
Jun 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.